Status:

COMPLETED

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

Lead Sponsor:

Milton S. Hershey Medical Center

Collaborating Sponsors:

GlaxoSmithKline

Conditions:

COPD

Eligibility:

All Genders

45-75 years

Phase:

PHASE4

Brief Summary

Fluticasone (Advair), an inhaled corticosteroid and salmeterol, a long-acting beta agonist, are approved for use in the management of COPD. Fluticasone/salmeterol has been shown to significantly impro...

Detailed Description

RATIONALE: Chronic obstructive pulmonary disease (COPD) is a term that describes a disease state in which there is chronic irreversible airflow limitation. It has been well documented that patients w...

Eligibility Criteria

Inclusion

  • Patients with moderate to severe COPD as per GOLD criteria
  • Insomnia, poor sleep, non-restorative sleep or daytime sleepiness by history
  • Age 45 to 75 years, male or female
  • FEV1 below 80% of predicted using CRAPO
  • FEV1/FVC \< 70% predicted
  • Past or present tobacco smoker
  • Female patients must be postmenopausal for 1 year or be willing to use birth control or abstain from sex.

Exclusion

  • Asthma
  • Use of oral or injectable corticosteroids within 2 months
  • Previous diagnosis of sleep disorder breathing (sleep apnea, narcolepsy, etc.)
  • Lung or heart disease except for COPD
  • Deviated nasal septum, nasal polyps or anatomic obstruction of the nose
  • Obesity defined as BMI \>30kg/m2
  • Inability to tolerate or history of allergy to long acting beta agonist or inhaled corticosteroid therapy.
  • Inability to complete a 2 week run-in with albuterol prn as only therapy
  • Use of narcotics, sleep aids, sedating antihistamines, sedatives, MAO Inhibitors, and other medications known to affect daytime somnolence or sleep quality
  • Excessive use of alcohol or use of "recreational drugs"
  • Use of narcotics, sleep aids, sedatives or sedating antihistamines.
  • Night shift workers
  • Women who are breast feeding or pregnant.

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 1 2010

Estimated Enrollment :

10 Patients enrolled

Trial Details

Trial ID

NCT00731770

Start Date

January 1 2009

End Date

April 1 2010

Last Update

March 29 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Penn State Universuty

Hershey, Pennsylvania, United States, 17033